Katherine S Panageas

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Initial treatment patterns over time for anaplastic oligodendroglial tumors
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, 3rd Floor, New York, NY 10021, USA
    Neuro Oncol 14:761-7. 2012
  2. ncbi request reprint Analysis of multiple 2x2 tables with site-specific periodontal data
    K S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, 3rd Floor, New York, NY 10021, USA
    J Dent Res 82:514-7. 2003
  3. doi request reprint Use of high technology imaging for surveillance of early stage breast cancer
    K S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, 3rd Floor, New York, NY 10021, USA
    Breast Cancer Res Treat 131:663-70. 2012
  4. ncbi request reprint An optimal two-stage phase II design utilizing complete and partial response information separately
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Control Clin Trials 23:367-79. 2002
  5. ncbi request reprint Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Stat Med 26:2017-35. 2007
  6. ncbi request reprint When you look matters: the effect of assessment schedule on progression-free survival
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, 3rd Fl, New York, NY 10021, USA
    J Natl Cancer Inst 99:428-32. 2007
  7. pmc International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors
    Andrew B Lassman
    Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Neuro Oncol 13:649-59. 2011
  8. ncbi request reprint Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study
    Wen Jen Hwu
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 103:2590-7. 2005
  9. ncbi request reprint Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Drugs Aging 22:785-91. 2005
  10. pmc Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas
    Fabio M Iwamoto
    The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 13:1244-51. 2011

Research Grants

  1. Analysis Methods for Volume-Outcome Studies
    Katherine Panageas; Fiscal Year: 2005

Detail Information

Publications97

  1. pmc Initial treatment patterns over time for anaplastic oligodendroglial tumors
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, 3rd Floor, New York, NY 10021, USA
    Neuro Oncol 14:761-7. 2012
    ..01), and frontal lobe predominance (P < .05). Limited level 1 evidence is currently available to guide treatment decisions, and ongoing phase III trials will be critical to understanding the optimal therapy...
  2. ncbi request reprint Analysis of multiple 2x2 tables with site-specific periodontal data
    K S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, 3rd Floor, New York, NY 10021, USA
    J Dent Res 82:514-7. 2003
    ..We illustrate these methods using a subset of data from a clinical trial examining the effects of scaling and root planing on levels of interleukin-1 beta...
  3. doi request reprint Use of high technology imaging for surveillance of early stage breast cancer
    K S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, 3rd Floor, New York, NY 10021, USA
    Breast Cancer Res Treat 131:663-70. 2012
    ..Strategies to foster judicious utilization of HTRI should be a priority...
  4. ncbi request reprint An optimal two-stage phase II design utilizing complete and partial response information separately
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Control Clin Trials 23:367-79. 2002
    ..Sample size tables are provided for parameter sets commonly used in the oncologic setting. Software is available by contacting the authors...
  5. ncbi request reprint Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Stat Med 26:2017-35. 2007
    ..By contrast, the cluster weighted GEE method is inefficient...
  6. ncbi request reprint When you look matters: the effect of assessment schedule on progression-free survival
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, 3rd Fl, New York, NY 10021, USA
    J Natl Cancer Inst 99:428-32. 2007
    ..The decision to use PFS as a primary endpoint should be made carefully when designing clinical trials, and investigators focused on a particular disease should develop consensus standards and strive for consistent surveillance intervals...
  7. pmc International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors
    Andrew B Lassman
    Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Neuro Oncol 13:649-59. 2011
    ..Combined CT + RT led to longer disease control and survival than did CT or RT alone in cases with no 1p19q deletion. Ongoing trials will address these issues prospectively...
  8. ncbi request reprint Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study
    Wen Jen Hwu
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 103:2590-7. 2005
    ..The current Phase II study examined the efficacy and safety of this combination in chemotherapy-naive patients with brain metastases...
  9. ncbi request reprint Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Drugs Aging 22:785-91. 2005
    ..We sought to determine the association between calculated creatinine clearance (CL(CR)) and grade 3 or 4 toxicities during adjuvant chemotherapy in women > or =65 years of age with breast cancer...
  10. pmc Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas
    Fabio M Iwamoto
    The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 13:1244-51. 2011
    ..4, P< .0001). Longitudinal increases in serum YKL-40 are associated with increased risk of death in patients with glioblastomas and anaplastic gliomas. YKL-40 is also a putative indicator of disease status in these patients...
  11. ncbi request reprint A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy
    Arti Hurria
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Am Geriatr Soc 54:1119-24. 2006
    ..To examine the toxicity experienced by a cohort of older women receiving adjuvant chemotherapy for breast cancer and the longitudinal effect on their functional status and quality of life (QOL)...
  12. ncbi request reprint Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer
    Monica N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:223-7. 2007
    ..We conducted a pilot trial to assess the feasibility of dose-dense chemotherapy consisting of a standard regime at 10- to 11-day intervals in the adjuvant/neoadjuvant setting. A 2-day window was allowed for scheduling logistics...
  13. doi request reprint Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas
    Fabio M Iwamoto
    The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Neurooncol 105:607-12. 2011
    ..Changes in serum MMP-9 were not associated with survival in the anaplastic glioma cohort. Serum MMP-9 showed no utility in determining glioma disease status and was not a clinically relevant prognostic marker of survival...
  14. ncbi request reprint Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Invest 23:483-7. 2005
    ..046). Functional assessment of HER2 status may provide unique predictive information not seen with conventional assessments...
  15. ncbi request reprint Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma
    Wen Jen Hwu
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 106:2445-51. 2006
    ..Therefore, the efficacy and safety of temozolomide in combination with pegylated IFN-alpha-2b in patients with metastatic melanoma without brain metastases was investigated...
  16. ncbi request reprint Patterns of treatment in older adults with primary central nervous system lymphoma
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 110:1338-44. 2007
    ..The objective of the current study was to identify factors associated with the receipt and type of treatment in a population-based cohort of older PCNSL patients...
  17. doi request reprint Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy
    Patrick G Morris
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 52:1891-7. 2011
    ..51). Similarly, there were no differences in response rates or overall survival according to MTX AUC, suggesting that intra-patient dose escalation to increase MTX exposure is unnecessary when our regimen is utilized...
  18. doi request reprint KIT as a therapeutic target in metastatic melanoma
    Richard D Carvajal
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    JAMA 305:2327-34. 2011
    ..We explored the effects of KIT inhibition using imatinib mesylate in this molecular subset of disease...
  19. ncbi request reprint A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 6:55-60. 2005
    ..Gemcitabine was delivered at a dose of 800 mg/m2 on days 1, 8, and 15 of a 28-day cycle until evidence of disease progression...
  20. ncbi request reprint Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma
    Wen Jen Hwu
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:3351-6. 2003
    ..To further investigate the efficacy and safety of temozolomide plus thalidomide in patients with metastatic melanoma without brain metastases...
  21. doi request reprint Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy
    Meltem Ekenel
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 113:1025-31. 2008
    ..Therefore, a retrospective study was conducted to assess the impact of consolidation treatment after a CR to initial induction chemotherapy on disease control and survival...
  22. doi request reprint Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up
    Lee K Tan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 26:1803-9. 2008
    ..However, there is no consensus regarding the optimal method for pathologic examination of SLN, or the prognostic significance of SLN micrometastases...
  23. ncbi request reprint The effect of clustering of outcomes on the association of procedure volume and surgical outcomes
    Katherine S Panageas
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Intern Med 139:658-65. 2003
    ....
  24. doi request reprint Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma
    Miguel Angel Perales
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 16:2022-9. 2008
    ..Responding T cells had an effector memory cell phenotype. Polyfunctional T cells were also demonstrated. At a median of 31 months follow-up, median survival has not been reached. Human GM-CSF DNA was found to be a safe adjuvant...
  25. ncbi request reprint Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort
    Elena B Elkin
    Health Outcomes Research Group and Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:2757-64. 2006
    ..Our goal was to assess the relationship between adjuvant chemotherapy use and survival in a large, population-based cohort of older women with hormone receptor (HR) -negative breast cancer...
  26. doi request reprint YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma
    Andreas F Hottinger
    Brain Tumor Center, New York, NY, USA
    Ann Neurol 70:163-9. 2011
    ..To evaluate YKL-40 and MMP-9 proteins as tumor biomarkers in serum samples from patients with primary central nervous system lymphoma (PCNSL)...
  27. ncbi request reprint Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Am Geriatr Soc 54:925-31. 2006
    ..To report on the longitudinal cognitive functioning of older women receiving adjuvant chemotherapy for breast cancer...
  28. doi request reprint Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience
    Douglas E Ney
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 116:4605-12. 2010
    ....
  29. ncbi request reprint Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Drugs Aging 22:709-15. 2005
    ..To determine the association between changes in complete blood counts and grade 3 or 4 toxicities from cycle 1 to cycle 2 during adjuvant chemotherapy in women > or =65 years of age with breast cancer...
  30. doi request reprint Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible
    Chau Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 8:418-24. 2008
    ..Dose-dense EC (without the 5-FU) is not associated with pneumonitis, and dose-dense paclitaxel (alone) is feasible. Primary objective was feasibility...
  31. doi request reprint Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection
    Brian A Ginsberg
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10065, USA
    Clin Cancer Res 16:4057-65. 2010
    ..To further define the optimal vaccination strategy, we conducted a pilot clinical trial comparing i.m. injection with particle-mediated epidermal delivery (PMED)...
  32. doi request reprint An increased number of sentinel lymph nodes is associated with advanced Breslow depth and lymphovascular invasion in patients with primary melanoma
    Carl R Schmidt
    Department of Surgery, Gastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg Oncol 16:948-52. 2009
    ..The pathologic status of the sentinel lymph node (SLN) is a powerful prognostic factor for patients with intermediate thickness melanoma. We hypothesize that a high number of SLNs identified may be associated with poor outcome...
  33. doi request reprint Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy
    T Peter Kingham
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 17:514-20. 2010
    ..This study evaluates the outcome of patients who had a positive SLN but did not undergo CLND at Memorial Sloan-Kettering Cancer Center...
  34. ncbi request reprint Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, NY 10021, New York, USA
    Breast Cancer Res Treat 92:151-6. 2005
    ..To retrospectively determine the relationship of age to toxicity from adjuvant chemotherapy for breast cancer...
  35. ncbi request reprint Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma
    Leah Ben-Porat
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 106:163-71. 2006
    ....
  36. ncbi request reprint Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane
    Monica N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1575-9. 2005
    ....
  37. pmc Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses
    Nicole Lamanna
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 27:491-7. 2009
    ..In that study, cyclophosphamide consolidation improved the frequency of complete response (CR) four-fold. Subsequently, rituximab was added to this regimen (F-->C-->R)...
  38. ncbi request reprint A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Breast Cancer Res Treat 90:157-63. 2005
    ..Breast cancer has variable expression of KIT and PDGFR therefore we conducted a phase II trial to evaluate the safety and efficacy of imatinib in patients with metastatic breast cancer (MBC)...
  39. ncbi request reprint Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer
    Chau T Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:5754-61. 2004
    ..The primary objective was to determine the feasibility of the regimen; the secondary objective was to estimate the disease-free and overall survival...
  40. pmc Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
    Antonio Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 15:242-50. 2013
    ..In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs)...
  41. doi request reprint Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma
    Ryan C Fields
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 118:3311-20. 2012
    ..Here, the authors describe their experience with a large cohort of patients who were treated at a single institution to describe patterns of recurrence after curative therapy...
  42. ncbi request reprint Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection
    Deborah Schrag
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Surg Oncol 83:68-78; discussion 78-9. 2003
    ..However, the importance of surgeon case volume as a determinant of outcome has been less well studied, and it is unclear whether hospital or surgeon volume is the more powerful predictor of outcomes...
  43. doi request reprint Recurrence and survival in patients undergoing sentinel lymph node biopsy for merkel cell carcinoma: analysis of 153 patients from a single institution
    Ryan C Fields
    Gastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 18:2529-37. 2011
    ..Merkel cell carcinoma (MCC) is a cutaneous neuroendocrine neoplasm with propensity for lymphatic spread. The rarity of MCC has limited analysis of factors associated with a positive sentinel lymph node biopsy (SLNB) and survival...
  44. ncbi request reprint HDM2 protein overexpression and prognosis in primary malignant melanoma
    David Polsky
    Department of Dermatology, Medical Center, New York University School of Medicine, 550 1st Avenue, New York, NY 10016, USA
    J Natl Cancer Inst 94:1803-6. 2002
    ..33 to 0.94; two-sided chi(2) P =.027) in multivariable analysis. HDM2 overexpression appears to be an independent predictor of survival for patients with primary melanoma; however, larger prospective studies are required for validation...
  45. ncbi request reprint Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial
    Wen Jen Hwu
    Departments of Medicine, Epidemiology and Biostatistics, and Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2610-5. 2002
    ..To establish a safe and tolerated regimen of an oral cytotoxic agent, temozolomide, and a cytostatic agent, thalidomide, in patients with unresectable stage III or IV malignant melanoma...
  46. pmc Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
    Jianda Yuan
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 108:16723-8. 2011
    ....
  47. ncbi request reprint Bcl-6 predicts improved prognosis in primary central nervous system lymphoma
    Oren Levy
    Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, New York, USA
    Cancer 112:151-6. 2008
    ..The objectives of this study were to characterize the immunophenotypes of PCNSL samples and to determine their utility in predicting clinical outcomes...
  48. pmc A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer
    Maura N Dickler
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:7878-83. 2008
    ..To evaluate the efficacy and toxicity of erlotinib plus bevacizumab in patients with metastatic breast cancer (MBC), targeting the epidermal growth factor receptor (EGFR/HER1) and the vascular endothelial growth factor (VEGF) pathway...
  49. ncbi request reprint Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection
    Deborah Schrag
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 98:163-71. 2006
    ..e., hospital or surgeon) procedure volumes and patient outcomes have been demonstrated for many types of cancer operation. We performed a population-based cohort study to examine these associations for ovarian cancer resections...
  50. ncbi request reprint Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments
    Chau T Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:4062-7. 2004
    ....
  51. doi request reprint Patterns of care in elderly glioblastoma patients
    Fabio M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Neurol 64:628-34. 2008
    ..To evaluate the patterns of care in elderly glioblastoma (GBM) patients from a large population-based registry...
  52. ncbi request reprint Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:5711-5. 2006
    ....
  53. pmc Cancer screening among patients with advanced cancer
    Camelia S Sima
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, Second Floor, New York, NY 10065, USA
    JAMA 304:1584-91. 2010
    ..Cancer screening has been integrated into routine primary care but does not benefit patients with limited life expectancy...
  54. ncbi request reprint Variates of survival in metastatic uveal melanoma
    Petra Rietschel
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:8076-80. 2005
    ..We evaluated the survival of our patients with metastatic uveal melanoma, described factors that correlated with survival, and evaluated the influence of screening tests on time of detection and survival...
  55. doi request reprint Prognosis and patterns of care in elderly patients with glioma
    Fabio M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 115:5534-40. 2009
    ..The current study was conducted to evaluate the patterns of care and survival of older adults with oligodendroglioma (OLI) and astrocytoma (AST) from a large population-based registry...
  56. pmc Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival
    Geoffrey Y Ku
    Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 116:1767-75. 2010
    ..The authors report on advanced refractory melanoma patients treated in a compassionate use trial of ipilimumab at the Memorial Sloan-Kettering Cancer Center...
  57. doi request reprint Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma
    Federica Catalanotti
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 19:2257-64. 2013
    ..Test the hypothesis that in BRAF-mutated melanomas, clinical responses to selumetinib, a MEK inhibitor, will be restricted to tumors in which the PI3K/AKT pathway is not activated...
  58. ncbi request reprint Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma
    Jedd D Wolchok
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 15:2044-50. 2007
    ..Mouse and human TYR DNA vaccines were found safe and induced CD8(+) T-cell responses in 7 of 18 patients. T cells recognizing a native TYR peptide had a phenotype consistent with that of effector memory cells...
  59. doi request reprint Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy
    Patrick G Morris
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Thorac Oncol 7:382-5. 2012
    ..A retrospective review was carried out to assess the impact of whole brain radiotherapy (WBRT), intrathecal therapy (IT), and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) on outcomes...
  60. doi request reprint Utility of lesion diameter in the clinical diagnosis of cutaneous melanoma
    Naheed R Abbasi
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, 550 First Ave, Room H 100, New York, NY 10016, USA
    Arch Dermatol 144:469-74. 2008
    ..To determine the utility of the current diameter criterion of larger than 6 mm of the ABCDE acronym for the early diagnosis of cutaneous melanoma...
  61. ncbi request reprint Systemic high-dose intravenous methotrexate for central nervous system metastases
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Neurooncol 78:255-60. 2006
    ..Rapid infusion of high-dose intravenous methotrexate (HD IV MTX) penetrates the blood-brain barrier (BBB) and has reported activity in leptomeningeal metastases...
  62. ncbi request reprint Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status
    Cristina R Ferrone
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg Oncol 9:637-45. 2002
    ....
  63. ncbi request reprint Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:2466-72. 2005
    ..The objective of this study was to examine time trends in overall survival and disease-specific mortality in a population-based cohort of patients with PCNSL...
  64. ncbi request reprint PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation
    Maryann Mikhail
    Department of Dermatology, New York University School of Medicine, New York, New York 10016, USA
    Clin Cancer Res 11:5153-7. 2005
    ..We investigated the clinical relevance of PTEN expression in the primary melanoma patients with extended follow-up...
  65. ncbi request reprint Clinicopathological features of and risk factors for multiple primary melanomas
    Cristina R Ferrone
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    JAMA 294:1647-54. 2005
    ..The incidence of multiple primary melanomas ranges from 1.3% to 8.0% in large retrospective reviews; however, the impact of certain risk factors is not understood...
  66. pmc Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo
    Emanuela Romano
    Laboratory of Cellular Immunobiology, Immunology Program, Sloan Kettering Institute for Cancer Research, New York, New York, USA
    Clin Cancer Res 17:1984-97. 2011
    ..We compared the efficacy of human Langerhans cells (LC) as tumor immunogens in vivo with monocyte-derived dendritic cells (moDC) and investigated how interleukin 15 (IL15) supports optimal DC-stimulated antitumor immunity...
  67. ncbi request reprint Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer
    Shanu Modi
    Breast Cancer Medicine Service, Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:3665-73. 2002
    ..To prospectively evaluate the association between tumor response, change in quality of life (QoL), and hospital expenditures in patients with metastatic breast cancer (MBC) receiving single-agent paclitaxel...
  68. pmc Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
    Todd L Rosenblat
    Department of Medicine and the Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:5303-11. 2010
    ..This phase I/II trial was conducted to determine the maximum tolerated dose (MTD) and antileukemic effects of (213)Bi-lintuzumab, the first targeted α-emitter, after partially cytoreductive chemotherapy...
  69. pmc Geographic access and the use of screening mammography
    Elena B Elkin
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Med Care 48:349-56. 2010
    ..Inadequate mammography resources in some areas may impair access to this technology. We assessed the relationship between availability of mammography machines and the use of screening...
  70. pmc Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response
    Gabrielle A Rizzuto
    Departments of Medicine and Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Exp Med 206:849-66. 2009
    ..Further, precursor frequency as an isolated variable can be exploited to augment efficacy of clinical vaccine strategies designed to activate any antigen-specific CD8(+) T cells...
  71. pmc Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma
    David B Solit
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 14:8302-7. 2008
    ..We conducted a phase II trial using the hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in melanoma patients. The primary end points were clinical responses and whether treatment inhibited MAPK pathway activity...
  72. ncbi request reprint A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy
    Michael W Kattan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 101:2509-15. 2004
    ....
  73. doi request reprint Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data
    Cami S Sima
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Appl Health Econ Health Policy 8:37-51. 2010
    ....
  74. ncbi request reprint Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma
    Rebecca C Taylor
    Departments of Surgery, Biostatistics, and Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 25:869-75. 2007
    ..The prognostic implications of TILs were re-evaluated in a large group of patients undergoing SLN biopsy at our institution...
  75. ncbi request reprint Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma
    Carole Hazan
    Ronald O Perelman Department of Dermatology, New York University School of Medicine Veterans Affairs Medical Center, 550 First Avenue, New York, NY 10010, USA
    Cancer 95:634-40. 2002
    ..Its utility in melanoma has been evaluated mostly in studies of thick primary tumors. Its usefulness in thinner lesions has not been assessed adequately...
  76. doi request reprint A SEER-Medicare population-based study of lymphedema-related claims incidence following breast cancer in men
    Anne S Reiner
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
    Breast Cancer Res Treat 130:301-6. 2011
    ..Lymphedema is a common complication affecting men with breast cancer as well as women and appropriate treatment and rehabilitation strategies need to be implemented for both genders...
  77. pmc (124)I-huA33 antibody PET of colorectal cancer
    Jorge A Carrasquillo
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Nucl Med 52:1173-80. 2011
    ..We also determined the biodistribution of (124)I-huA33 when a large dose of human intravenous IgG (IVIG) was administered to manipulate the Fc receptor or when (124)I-huA33 was given via hepatic arterial infusion (HAI)...
  78. ncbi request reprint Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response
    George Sgouros
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 44:260-8. 2003
    ....
  79. ncbi request reprint A statistical perspective on gene expression data analysis
    Jaya M Satagopan
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Stat Med 22:481-99. 2003
    ..S-plus and SAS codes to perform the statistical methods are provided. Gene expression data from an unpublished oncologic study is used to illustrate these methods...
  80. ncbi request reprint Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer
    Catherine Van Poznak
    Breast Cancer Medicine Service, The Pathology Department, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2319-26. 2002
    ..g., HER2, EGFR), and estrogen receptors and progesterone receptors. These molecular markers and their correlation with clinical taxane sensitivity are investigated in this retrospective clinicopathologic study...
  81. pmc Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid
    Jae H Park
    Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 118:1248-54. 2011
    ..These data highlight a need to educate health care providers across a wide range of medical fields, who may be the first to evaluate patients with APL, to have a major effect on early death and the cure rate of APL...
  82. ncbi request reprint Developing a cancer-specific geriatric assessment: a feasibility study
    Arti Hurria
    Department of Medicine, Psychiatry and Behavioral Sciences, and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1998-2005. 2005
    ....
  83. ncbi request reprint Identifying and addressing barriers to the delivery of optimal therapy for primary central nervous system lymphoma in the broader community
    Lauren E Abrey
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Leuk Lymphoma 47:2449-52. 2006
    ..We have sought to elaborate some potential causes of these disparities; however, future studies are needed to identify and address specific barriers to care in the community...
  84. ncbi request reprint YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas
    Adilia Hormigo
    Clinical Laboratories, Neurosurgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Clin Cancer Res 12:5698-704. 2006
    ..We obtained prospective longitudinal serum samples from patients with gliomas to determine whether YKL-40 or MMP-9 could be used as serum markers...
  85. doi request reprint How to build and interpret a nomogram for cancer prognosis
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, 3rd Floor, New York, NY 10021, USA
    J Clin Oncol 26:1364-70. 2008
    ..This guide provides a nonstatistical audience with a methodological approach for building, interpreting, and using nomograms to estimate cancer prognosis or other health outcomes...
  86. ncbi request reprint Ductal lavage in patients undergoing mastectomy for mammary carcinoma: a correlative study
    Edi Brogi
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 98:2170-6. 2003
    ..Ductal lavage (DL) is a new method for the sampling of breast epithelium. Data regarding its sensitivity in the detection of epithelial abnormalities, including carcinoma in situ (CIS), remains limited...
  87. pmc Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection
    Deborah Schrag
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Department of Medicine, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 236:583-92. 2002
    ..To compare surgeon and hospital procedure volume as predictors of outcomes for patients with rectal cancer...
  88. doi request reprint Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma
    Teri N Kreisl
    Neuro Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Leuk Lymphoma 49:1710-6. 2008
    ..028). Despite improved treatment for both diseases over the past decade, survival remains dismal in this cohort of Medicare/Medicaid beneficiaries with HIV-related PCNSL. These results may not apply to the general HIV population...
  89. ncbi request reprint T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants
    Susanne G Schaed
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:967-72. 2002
    ....
  90. doi request reprint Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy
    Kimberly Moore Dalal
    Department of Surgery, David Grant United States Air Force Medical Center, Travis AFB, CA, USA
    Ann Surg Oncol 15:2206-14. 2008
    ..An understanding of the methods of detection of recurrent melanoma after sentinel lymph node biopsy (SLNB) is essential for the coordination of a rational plan of follow-up...
  91. ncbi request reprint Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma
    William G Hawkins
    Department of Surgery, Washington University, St Louis, Missouri 63110, USA
    Ann Surg Oncol 12:207-13. 2005
    ..Pathologic heterogeneity within DM may account for the controversy regarding the clinical presentation and prognosis of DM compared with conventional melanoma (CM)...
  92. pmc Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features
    Jeffrey J Raizer
    Feinberg School of Medicine, Department of Neurology, Northwestern University, 710 North Lake Shore Drive, Chicago, IL 60611, USA
    Neuro Oncol 10:199-207. 2008
    ..The prognostic factors identified in this retrospective study should be considered when making treatment decisions for patients with BM and used as stratification factors in future clinical trials...
  93. ncbi request reprint Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia
    Nicole Lamanna
    Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:1575-81. 2006
    ..We previously reported that pentostatin and cyclophosphamide (PC) is active and well-tolerated in patients with relapsed or refractory CLL. Subsequently, we added rituximab, and now report on this three-drug combination...
  94. ncbi request reprint Delayed neurotoxicity in primary central nervous system lymphoma
    Antonio M P Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Arch Neurol 62:1595-600. 2005
    ..This delayed neurotoxicity has been poorly defined in the literature, and the underlying mechanisms are unknown...
  95. ncbi request reprint Treatment of spinal involvement in neuroblastoma patients
    David I Sandberg
    Department of Surgery, Division of Neurosurgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, N Y 10021, USA
    Pediatr Neurosurg 39:291-8. 2003
    ..Considerable controversy exists regarding the appropriate management of spinal involvement in neuroblastoma (NB) patients. We review a large group of such patients and offer treatment recommendations...
  96. ncbi request reprint Results of preoperative embolization for metastatic spinal neoplasms
    Vikram C Prabhu
    Section of Neurosurgery, University of Nebraska Medical Center, Omaha, Nebraska, USA
    J Neurosurg 98:156-64. 2003
    ..The objectives of this study were twofold: 1) to evaluate the role of magnetic resonance (MR) imaging in predicting tumor vascularity and 2) to assess the effectiveness of preoperative embolization in devascularizing these tumors...
  97. ncbi request reprint Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1
    Cristina Musselli
    Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 97:660-7. 2002
    ..Assuming this criteria, convincing induction of T-cell immunity against MUC1 by vaccination has yet to be described...

Research Grants1

  1. Analysis Methods for Volume-Outcome Studies
    Katherine Panageas; Fiscal Year: 2005
    ..Our methodological research will heighten awareness of clustering in health policy studies. Upon completion of our research plan, we will make recommendations about various analytic strategies for clustered binary data. ..